INIS 最新10-Q变化

相对上期新增的文字 · 来源:10-Q · 2026-05-20

• In our Medical Devices segment, we are currently sell various 3rd party products and we are developing our own products for commercial use, including an I-131 encapsulation system and Radvent devices.

• In our Fluorine Products segment, we are currently evaluating the possibility of fund raising, joint venturing, or divesting these assets, as discussed in more detail below.

• On March 11, 2026, we executed a mutual termination of the DUF6 Asset Sale dated February 8, 2024 to sell all our assets related to the Fluorine Products segment and the Planned Uranium De-Conversion Facility to AFR. AFR contacted the Company requesting a 1-year extension due to AFR being unable to …

• Three Months Ended March 31, 2026, Compared to Three Months Ended March 31, 2025

• Sale of Product for the three months ended March 31, 2026 was $2,378,924 as compared to $3,238,900 for the same period in 2025, an overall decrease of $859,976, or approximately 27%. This decrease in sales was the result of lost sales in our Theranostics Products segment due to voluntary recalls of …

相对上期删除的文字 · 来源:10-Q · 2025-11-14

• In our Medical Devices segment, we are currently developing products for commercial use, including an automated capsule system and medical molds and devices for applications in the theranostic medical radioisotope industry.

• We are currently in the process of divesting our Fluorine Products segment, as discussed in more detail below.

• On February 8, 2024, we entered into a definitive agreement to sell all our assets related to the Fluorine Products segment and the Planned Uranium De-Conversion Facility to American Fuel Resources (the “DUF6 Asset Sale”) for cash consideration of $12.5 million. On September 30, 2025, we and the buy…

• Related to the Fluorine Products’ assets, during 2024, we received $50,000 of other income related to the DUF6 Asset Sale and incurred $109,187 of expenses related to maintaining licenses and permits for the proposed de-conversion project, as compared to $7,920 of other income and $113,019 of expens…

• We expect the disposition of the Fluorine Products’ assets to bring in $12.45 million in gross consideration, recognizing a gain on the sale of assets of $7.5 million. We currently expect to use some of the proceeds to repay various long-term notes, totaling $1.62 million in principal and approximat…

相对上期新增的文字 · 来源:10-Q · 2026-05-20

• Starting in January 2024, there has been a continuing global outage of gadolinium-153, a key isotope for our Calibration & Reference Products segment. We are working on establishing new suppliers and believe that we will be able to have supply restored by the end of 2026; however. if we are unable t…

• In the three months ended March 31, 2026, we had two product recalls. Both recalls are being conducted with the knowledge of the FDA. The first was a voluntary recall of our Generic Sodium Iodide I-131 due to the discovery of septum in our finished product vials on January 26, 2026. We had recently …

• We are subject to ongoing NRC regulations, including complying with the NRC’s current Code of Federal Regulations (CFR) requirements, and are subject to regular inspections of our facilities. The NRC may take enforcement action in the event that we are found to be in violation of NRC regulations or …

相对上期删除的文字 · 来源:10-Q · 2025-11-14

• During the year ended December 31, 2024, there was a global shortage of cobalt-57, a key isotope for our Calibration & Reference Products segment. This shortage occurred from January 2024 until the end of July 2024 and resulted in significant loss of sales for our Calibration & Reference Products se…

• Starting in January 2024, there has been a continuing global outage of gadolinium-153, a key isotope for our Calibration & Reference Products segment. We are working on establishing new suppliers and believe that we will be able to have supply restored by 2026; however. if we are unable to do so, we…